NT Mobile Menu

Search form




The 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is taking place in London, United Kindom from September 14-17, 2016


Three new multiple sclerosis studies show the promise of two drugs, amiselimod and alemtuzumab, as treatments and one, arbaclofen, for spasticity.

Our Sept. news includes a possible clinical marker and therapy target in Alzheimer disease and MS findings from an optical coherence tomography study.

Research presented at this ECTRIMS session covered management of multiple sclerosis-related fatigue, cognitive issues, and gait impairment.

This ECTRIMS session includes studies using 7T and 3T MRI images and translocator protein PET scans, as well as phenotypes in gray matter and more.

Hot Topics session at ECTRIMS 2016: treat early active RRMS with potent induction therapy or immunomodulation then escalation? Where do you stand?

The session featured a study comparing MRI criteria for diagnosing MS, the role of spinal cord volume loss in predicting disease activity, and more.

Subscribe to ECTRIMS 2016 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.